Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021 On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr

• Is Rituximab and Belimumab the Combination to Beat Lupus? | RheumNow

➡️Percentage achieving PASI75 (not H2H comparison): ⭐️GUS > IXE > INF > SEC > UST > GOL 100mg >ADA> CTZ > TOFA> GOL 50 mg > ETN > APR ⭐️Amongst TNFi (not H2H): INF > GOL > ADA > CTZ > ETN Great talk by Dr. L Coates on personalized tx approach for PsA. #EULAR2021 @RheumNow https://t.co/jMGaBlg3Iy

➡️%age achieving ACR20 (not H2H comparisons): ⭐️GUS > IXE > TOFA > CTZ > ETN > INF > ADA > SEC > GOL > UST > APR ➡️ Choosing therapies in AxSpA: ⭐️TNFi (ADA), IL17i (SEC), Jaki (UPA); however, axPsA may be different than AxSpA. Need more trials to assess! #EULAR2021 @RheumNow https://t.co/toMyS3uPAZ

How to choose therapy for psoriatic dz? ➡️Should be a personalized approach based on co-morbidities ➡️Below drugs are approved for primary therapy of co-morbid condition: ⭐️IBD: SSZ, ADA, INF. GOL for UC, UST for Crohn's ⭐️Uveitis: GCs & INF preferred, ADA #EULAR2021 @RheumNow https://t.co/inN07QP9t4

Step-wise vs rapid escalator approach for PsO & PsA? ⭐️CONTROL study: ➡️bDMARD-naive active PsA w/ IR to MTX for at least 4w randomized to ADA+MTX vs escalated MTX (avg dose 21.8 mg/wk, 55% PO, 36% SQ) ➡️41.5% MDA at wk 16 w/ ADA+MTX vs 13.1% #EULAR2021 @RheumNow https://t.co/uw5BFQGqNV

❗️Dismal trend in #scleroderma survival ➡️38 y data from @Olmstedcounty An URGENT call for better therapeutics 👉 2.5 fold>general population 👉 NO trend for improved survival 👉 Age, Smoking, Digital Ischemia, ILD and PAH Check out 👉POS0838 #EULAR2021 #CaitrinCoffey https://t.co/KDStYRI6nz

Osteoarthritis related bio markers associated with MRI imaging biomarkers ⭐️COMP and MMP-3 negatively associated with knee cartilage thickness ⭐️serum biomarkers could predict future MRI based markers Abs#POS0129 #EULAR2021 @RheumNow

If a patient w/ PsA has high disease activity, would you take the rapid escalator approach (bDMARD) or a step-wise approach (csDMARD to start & escalate per response)? Be sure to check out Dr. L Coates great talk on personalized tx approach! #EULAR2021 @RheumNow @ElaineHusniMD

Can biologics change our gut microbiome? TNFi in IBD related SpA study ⭐️⬇️proteobacteria, ⬆️lachnospiraceae ⭐️TNFi could restore intestinal eubiosis Abs#POS0230 #EULAR2021 @RheumNow

Can we act on modifiable predictors of PsA? ⭐️Higher BMI associated with PsA progression from PsO ⭐️family history of PsA, nail pitting predicted PsA development Abs#POS0145 #EULAR2021 @RheumNow

How to Watch EULAR 2021 with Dr. Jack Cush Listen to RheumNow editor Dr. Jack Cush talk about how to take in all the amazing EULAR 2021 content and information this week. #EULAR2021 https://t.co/cXwUO7J9YS https://t.co/JAieLdAnyb

• https://bit.ly/3uNhPEU

#EULAR2021 – Day 2 Report During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more. Read our highlights. https://t.co/NbBqPbbiUy https://t.co/1m6R9F7XWf

• https://bit.ly/3uNgYnG

Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021 On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr

• https://bit.ly/3z5kNrB